Before benzodiazepines supplanted them in the 1960s and 1970s, barbiturates dominated sedative-hypnotic pharmacotherapy for nearly a century. Their limitations — narrow therapeutic index, profound respiratory depression, lethal toxicity in overdose, and severe dependence liability — drove their displacement from general sedative and hypnotic practice. Nevertheless, barbiturates retain meaningful, well-defined clinical roles: phenobarbital remains a first-line anticonvulsant in neonatal seizures and a critical agent in refractory status epilepticus and sedative-hypnotic withdrawal management; thiopental and pentobarbital retain niche procedural and neurocritical care applications; and phenobarbital's role in alcohol and benzodiazepine withdrawal is experiencing a significant clinical resurgence.1
Beyond barbiturates, a constellation of older sedative agents — chloral hydrate, meprobamate, and buspirone — warrant pharmacological understanding, whether because of historical clinical significance, residual use in specific settings, or because their mechanisms illuminate broader principles of CNS pharmacology. And in contemporary hospital and procedural medicine, a distinct group of intravenous sedative-hypnotics — propofol, dexmedetomidine, ketamine, and etomidate — are essential tools in the clinician's armamentarium whose mechanisms, clinical profiles, and safety considerations are fundamental knowledge for any inpatient or procedural clinician.
This module covers the pharmacology of barbiturates and their current clinical applications, the pharmacological legacy of older sedative agents, and the mechanisms and clinical use of IV anesthetic sedatives, including a structured overview of the sedation continuum and monitoring principles.
Barbiturates, like benzodiazepines, act at the GABA-A receptor (GABA-A) — but at a distinct binding site and through a different mechanism. While benzodiazepines bind at the α-γ subunit interface and increase the frequency of chloride channel opening in the presence of GABA, barbiturates bind within the chloride channel pore itself (at sites on the β subunit transmembrane domains) and increase the duration of channel opening.2 This mechanistic distinction has critical pharmacological consequences.
At therapeutic concentrations, barbiturates require GABA to be present and potentiate GABA-A receptor-mediated chloride influx by prolonging channel opening time — analogous to the allosteric modulatory effect of benzodiazepines in this respect. However, at higher (supratherapeutic) concentrations, barbiturates can directly activate the GABA-A chloride channel in the absence of GABA, functioning as direct channel activators rather than purely allosteric modulators.2 This GABA-independent direct activation at high concentrations is the mechanistic basis for the profound, dose-dependent CNS depression that characterizes barbiturate toxicity — respiratory depression, cardiovascular collapse, and death — and is precisely what benzodiazepines cannot do at any dose (due to their absolute dependence on endogenous GABA). The therapeutic index of barbiturates is consequently far narrower than that of benzodiazepines, and the lethality of barbiturate overdose as monotherapy is substantially greater.
In addition to their GABA-A potentiating effects, barbiturates also inhibit AMPA-type glutamate receptors at clinically relevant concentrations, contributing to their anticonvulsant and anesthetic properties through a dual mechanism of enhancing inhibition and suppressing excitation.3 This dual action is particularly relevant to their efficacy in refractory status epilepticus, where benzodiazepine-resistant seizures may partially reflect GABA-A receptor internalization and reduced GABA-A responsiveness — a state in which glutamate receptor antagonism provides an alternative mechanistic approach.
PHARMACOKINETIC OVERVIEW: Barbiturates are broadly classified by duration of action into ultra-short-acting (thiopental, methohexital — IV anesthetics, onset seconds, duration minutes), short-acting (secobarbital, pentobarbital — historical hypnotics, onset 10–15 minutes, duration 3–4 hours), intermediate-acting (amobarbital, butabarbital), and long-acting (phenobarbital — t½ 80–120 hours; primidone, which is metabolized to phenobarbital). All barbiturates are hepatically metabolized, and phenobarbital is a potent inducer of CYP1A2 (cytochrome P450 1A2), CYP2C9 (cytochrome P450 2C9), CYP2C19 (cytochrome P450 2C19), CYP3A4 (cytochrome P450 3A4), and P-glycoprotein — making it one of the most clinically significant drug interaction agents in pharmacology, capable of dramatically reducing the plasma levels of a wide range of co-administered drugs including warfarin, oral contraceptives, antiretrovirals, and many anticonvulsants.1
PHENOBARBITAL — EPILEPSY AND SEIZURE MANAGEMENT:
Phenobarbital is one of the oldest anticonvulsants in clinical use (introduced 1912) and remains a first-line agent in several specific clinical contexts despite its displacement by newer agents in general epilepsy practice.1 Its primary current indications include:
Neonatal seizures: Phenobarbital remains the first-line treatment for neonatal seizures, including hypoxic-ischemic encephalopathy (HIE)-associated seizures, in most institutions. IV loading dose of 20 mg/kg achieves rapid therapeutic levels (20–40 mcg/mL); additional 5 mg/kg doses may be given to a maximum of 40 mg/kg if seizures persist.4 Maintenance dosing (3–5 mg/kg/day, IV or PO) is initiated after the loading dose. The rationale for phenobarbital's particular effectiveness in neonatal seizures relates partly to neonatal GABA-A receptor (GABA-A) physiology: in the immature brain, GABA-A receptor activation produces depolarization rather than hyperpolarization (due to high intracellular chloride in neonatal neurons), which paradoxically renders standard GABAergic agents partially excitatory in neonates. Phenobarbital's additional AMPA receptor antagonism may contribute to its efficacy in this context.3
Refractory status epilepticus: When benzodiazepines and second-line agents (fosphenytoin, valproate, levetiracetam, lacosamide) fail to terminate status epilepticus, IV phenobarbital (20 mg/kg IV at maximum 50–100 mg/min) is a recognized third-line agent, with efficacy attributable to its dual mechanism of GABA-A potentiation and AMPA receptor antagonism.3 The risk of respiratory depression and hypotension at these doses requires intubation readiness.
Resource-limited settings: Phenobarbital's low cost, oral bioavailability, and once-daily dosing make it the most widely available anticonvulsant globally, and it remains a standard first-line agent in many low- and middle-income countries.
Alcohol and benzodiazepine withdrawal: Phenobarbital loading for the management of alcohol withdrawal syndrome is experiencing a significant evidence-based resurgence, particularly in emergency department and ICU settings. Fixed-dose IV phenobarbital loading (typically 10 mg/kg up to 15 mg/kg administered over 30–60 minutes) has been shown in prospective and retrospective studies to reduce benzodiazepine requirements, ICU admission rates, and incidence of delirium tremens compared to benzodiazepine-only protocols.5 The pharmacological rationale is compelling: phenobarbital directly activates GABA-A channels at high concentrations (bypassing the receptor downregulation that reduces benzodiazepine efficacy in severe withdrawal), inhibits AMPA receptors (attenuating excitatory withdrawal pathophysiology), and has a long half-life providing smooth, self-tapering coverage. Full discussion of withdrawal protocols is provided in CNS-04.
Drug interactions: Phenobarbital's potent CYP induction profile is clinically critical. Major interactions include: markedly reduced warfarin efficacy (international normalized ratio (INR) monitoring and dose adjustment required); reduced efficacy of hormonal contraceptives (alternative contraception required); reduced levels of many antiretroviral agents; reduced efficacy of newer anticonvulsants including lamotrigine, tiagabine, and zonisamide; and complex interactions with valproate (phenobarbital levels may increase while valproate levels decrease).1 Phenobarbital induction of cytochrome P450 (CYP450) enzymes also accelerates its own metabolism to some extent (auto-induction, though less pronounced than carbamazepine).
THIOPENTAL AND PENTOBARBITAL:
Thiopental (sodium thiopentate): An ultra-short-acting barbiturate historically used for induction of general anesthesia and for rapid sequence intubation. Its extreme lipophilicity produces unconsciousness within one arm-brain circulation time (approximately 30 seconds) after IV administration, with rapid offset due to redistribution from brain to peripheral tissues (duration 5–10 minutes). Although largely supplanted by propofol for routine anesthesia induction due to propofol's more favorable adverse effect profile and lack of accumulation, thiopental retains limited use in refractory status epilepticus (barbiturate coma) and in some jurisdictions for specific procedural indications. Thiopental is not commercially available in the US; its use in the US has been effectively discontinued since the mid-2000s due to supply discontinuation.
Pentobarbital: A short-to-intermediate-acting barbiturate used in two specific contemporary clinical contexts: (1) procedural sedation in pediatric patients for diagnostic imaging (CT, MRI), particularly in settings where its longer duration compared to propofol is an advantage and where personnel with anesthetic training administer it; and (2) pentobarbital coma (refractory intracranial hypertension) in neurocritical care, where deep barbiturate sedation is used to reduce cerebral metabolic rate and intracranial pressure in patients with refractory traumatic brain injury or refractory status epilepticus.6 Pentobarbital coma requires continuous EEG monitoring for burst suppression titration, continuous hemodynamic monitoring, and mechanical ventilation.
CHLORAL HYDRATE: Chloral hydrate was introduced in 1869 as one of the first synthetic sedative-hypnotics and was in widespread use for over a century. Its mechanism involves conversion to the active metabolite trichloroethanol, which potentiates GABA-A receptor (GABA-A) activity through a mechanism similar to barbiturates.7 Chloral hydrate produces sedation with a relatively narrow therapeutic window and a toxic dose approximately five times the hypnotic dose. Contemporary use has been largely abandoned due to GI irritation (nausea, vomiting), cardiac arrhythmia risk at higher doses, potential carcinogenicity of metabolites with chronic use, and fatal overdose risk. In the US, the primary remaining application was pediatric procedural sedation — particularly for short radiological procedures and dental sedation in children — but this use has steadily declined as safer alternatives (intranasal dexmedetomidine, oral midazolam, propofol by trained anesthesiologists) have become available. The FDA issued safety communications citing concerns about chloral hydrate's use in pediatric sedation, and many institutions have phased it out entirely.
MEPROBAMATE (Miltown, Equanil): Meprobamate is a carbamate compound introduced in the 1950s as an anxiolytic and sedative, marketed as the first "tranquilizer" and enormously popular in its era. Its mechanism is similar to barbiturates (GABA-A potentiation, possibly through a distinct binding site from barbiturates) and it also inhibits NMDA receptors. Meprobamate has significant abuse potential, causes physical dependence with a withdrawal syndrome similar to alcohol and barbiturates, and carries a narrow therapeutic index. It remains a Schedule IV controlled substance and is still occasionally encountered in elderly patients maintained on decades-old prescriptions. Its clinical use today is essentially nil, and no current clinical guidelines endorse it for any indication. Clinicians encountering patients on meprobamate should initiate a supervised taper, as abrupt discontinuation can cause severe withdrawal including seizures.
BUSPIRONE (BuSpar): Buspirone occupies a unique pharmacological position among agents discussed in this series — it is not sedating in the traditional sense and bears no mechanistic resemblance to GABA-A modulators or barbiturates. It is a partial agonist at 5-HT1A serotonin receptor (HT1A) serotonin receptors (in postsynaptic limbic areas, where it inhibits serotonergic activity) and an antagonist at presynaptic 5-HT1A autoreceptors (which increases serotonin release), producing net anxiolytic effects through serotonergic modulation rather than GABAergic inhibition.8 It also has dopamine D2 receptor antagonist activity at higher doses. Buspirone is FDA-approved for generalized anxiety disorder and produces anxiolysis without sedation, cognitive impairment, muscle relaxation, or anticonvulsant effects. Buspirone has no dependence liability and no cross-tolerance with benzodiazepines or alcohol — meaning it will not prevent or treat alcohol or benzodiazepine withdrawal, and a patient switching from a benzodiazepine to buspirone must be tapered off the benzodiazepine separately. Onset of anxiolytic effect is delayed 1–4 weeks, making it unsuitable for acute anxiety management. It is not a hypnotic and has no role in insomnia treatment. Its primary clinical value is as a long-term anxiolytic in patients where benzodiazepine dependence, cognitive impairment, or substance use history makes benzodiazepines problematic.
PROPOFOL (Diprivan): Propofol is the most widely used intravenous sedative-hypnotic in contemporary clinical practice, serving as the standard induction agent for general anesthesia and a first-line agent for procedural sedation and ICU sedation.9 Its mechanism is predominantly through potentiation of GABA-A receptor (GABA-A) chloride channel conductance, though it may also inhibit NMDA receptors and sodium channels at clinical concentrations. Propofol's distinctive pharmacokinetic profile — extremely rapid onset (15–45 seconds IV), rapid redistribution, and short context-sensitive half-life (approximately 2–24 minutes after short infusions, extending with prolonged infusions due to peripheral compartment accumulation) — makes it highly controllable. It undergoes extensive hepatic metabolism (CYP2B6 (cytochrome P450 2B6) primarily) and conjugation to inactive glucuronides; clearance exceeds hepatic blood flow, suggesting significant extrahepatic metabolism.
Clinical properties: Propofol produces dose-dependent CNS depression from anxiolysis through general anesthesia. It has antiemetic properties (useful in patients at high risk for postoperative nausea and vomiting), amnestic properties, and anti-pruritic effects. It does not provide analgesia and should be combined with opioids or other analgesics when pain management is required alongside sedation.
Adverse effects: Propofol produces dose-dependent respiratory depression and apnea, particularly at induction doses — airway management capability is mandatory. Hypotension is common, mediated by decreased systemic vascular resistance and mild myocardial depression; this is particularly pronounced in hypovolemic or elderly patients. Pain on injection is common (reduced by pretreatment with IV lidocaine or using a larger vein). Propofol is formulated in a lipid emulsion (soybean oil, egg lecithin), which serves as a medium for microbial growth if aseptic technique is not rigorously maintained — contaminated propofol infusions have caused serious infections and fatalities.
Propofol infusion syndrome (PRIS): A rare but life-threatening complication of prolonged high-dose propofol infusions (typically >48 hours at >5 mg/kg/hour), characterized by severe metabolic acidosis, rhabdomyolysis, hyperkalemia, cardiac arrhythmias (particularly right bundle branch block and ST changes), renal failure, and potentially fatal cardiac failure.10 The mechanism involves impaired mitochondrial fatty acid oxidation and disruption of the electron transport chain. PRIS risk factors include high doses, prolonged use, critical illness (particularly sepsis and traumatic brain injury), use in children, and concomitant catecholamine or corticosteroid infusions. Total daily propofol dose should be tracked in ICU patients (expressed as mg/kg/hour), and doses approaching the 5 mg/kg/hour threshold should prompt reassessment, dose reduction, or transition to an alternative sedative.
DEXMEDETOMIDINE (Precedex): Dexmedetomidine is a highly selective α2-adrenergic receptor agonist that produces sedation, analgesia, and anxiolysis through a mechanism entirely distinct from GABA-A modulation.11 It acts primarily on α2 receptors in the locus coeruleus — the principal noradrenergic nucleus governing arousal — to inhibit norepinephrine release, thereby reducing ascending arousal signaling to the cortex and producing a state of sedation that closely resembles natural sleep. α2 receptors in the spinal cord contribute to its analgesic effects. Uniquely among IV sedatives, dexmedetomidine produces sedation from which patients can be readily aroused and cooperative — allowing neurological assessment and patient interaction during sedation, which is not possible with propofol or benzodiazepine-based sedation at comparable sedation depths.
Clinical applications: Dexmedetomidine is FDA-approved for ICU sedation (up to 24 hours, though real-world use commonly extends beyond this) and procedural sedation. It is particularly valuable in clinical scenarios where the ability to arouse the patient for neurological assessment is critical (e.g., neurosurgical ICU), where avoiding respiratory depression is important (it produces significantly less respiratory depression than propofol or opioids at sedating doses — though apnea can occur at high doses or with rapid loading), and for procedures requiring patient cooperation (e.g., awake craniotomy, bronchoscopy). It is also used for alcohol and opioid withdrawal management as an adjunct, given its sympatholytic properties.11
Adverse effects: Bradycardia and hypotension are the primary hemodynamic adverse effects, mediated by α2-mediated inhibition of sympathetic outflow. These are particularly pronounced with rapid IV loading; a loading dose (0.5–1 mcg/kg over 10–20 minutes) is used in some protocols but may be omitted in hemodynamically unstable patients. Transient hypertension may paradoxically occur at the onset of a rapid bolus due to peripheral vascular α2B receptor stimulation before central sympatholytic effects predominate.
KETAMINE: Ketamine is a dissociative anesthetic whose primary mechanism is non-competitive antagonism of NMDA glutamate receptors (specifically at the phencyclidine binding site within the open channel pore), blocking calcium influx through the NMDA channel and interrupting excitatory neurotransmission.12 Unlike all other IV sedatives discussed, ketamine increases sympathetic tone (inhibiting neuronal catecholamine reuptake), producing increases in heart rate, blood pressure, and cardiac output — making it the induction agent of choice in hemodynamically compromised patients (hemorrhagic shock, severe bronchospasm, cardiac tamponade). Ketamine also produces profound analgesia at subanesthetic doses, making it valuable for procedural analgesia, multimodal analgesia in the ICU, and as a component of total intravenous anesthesia.
Unique clinical properties: Ketamine produces a dissociative state characterized by a trance-like catalepsy, analgesia, amnesia, and sedation while maintaining airway protective reflexes (though this is not absolute, and airway management capability must always be available). Bronchodilation via sympathomimetic effects makes ketamine the agent of choice for procedural sedation in patients with severe reactive airway disease.12 Ketamine increases cerebral blood flow and has historically been avoided in patients with elevated intracranial pressure (ICP), but this contraindication has been substantially re-evaluated — current evidence suggests ketamine may be safely used in patients with intracranial hypertension when combined with adequate ventilation and other ICP management.
Adverse effects: Emergence reactions — vivid, often disturbing dreams, hallucinations, and delirium during recovery — are the most clinically problematic adverse effects and occur in approximately 10–15% of patients at anesthetic doses.12 They are most common in adults (less common in children), at higher doses, and with rapid administration. Pre-treatment or co-administration with a benzodiazepine (midazolam) substantially reduces emergence phenomenon incidence. Increased oral secretions (sialorrhea) are common; an anticholinergic agent (glycopyrrolate) can be used prophylactically. Elevated IOP and potential worsening of psychiatric conditions (psychosis, schizophrenia) are relative contraindications.
At sub-dissociative doses (0.1–0.3 mg/kg IV administered over 10–15 minutes), ketamine produces significant analgesia without the full dissociative state, emergence reactions, or pronounced sympathomimetic effects associated with anesthetic doses. Multiple randomized controlled trials have demonstrated non-inferiority of sub-dissociative ketamine to IV morphine for acute pain control in emergency departments, with a more favorable adverse effect profile including less nausea, vomiting, and respiratory depression, and significant reduction in opioid requirements when used as part of multimodal analgesia.12 In the ICU, ketamine infusions at analgesic doses (0.1–0.2 mg/kg/hour) reduce opioid consumption in mechanically ventilated patients, particularly those with opioid tolerance, opioid use disorder, or conditions where opioid minimization is a clinical priority.
The most significant emerging application of ketamine outside anesthesia is treatment-resistant depression (TRD). IV ketamine infusions (0.5 mg/kg over 40 minutes, repeated 2–3 times per week for 2–3 weeks) produce rapid antidepressant effects within hours of administration — in contrast to the 2–6 week latency of conventional antidepressants — a clinically transformative property for acutely suicidal patients.12 The antidepressant mechanism involves NMDA receptor blockade in prefrontal cortical circuits with downstream activation of AMPA receptors and brain-derived neurotrophic factor (BDNF) signaling, promoting synaptogenesis. Esketamine (Spravato), the S-enantiomer of racemic ketamine, is FDA-approved as an intranasal formulation for TRD and major depressive disorder with acute suicidality, administered in a certified healthcare setting under observation. The durability of ketamine's antidepressant effect is limited (typically days to weeks), and optimal maintenance strategies remain under investigation. Clinicians in primary care and emergency settings should be aware of ketamine's expanding psychiatric role and the availability of esketamine as an acute treatment option for patients failing multiple antidepressant trials.
ETOMIDATE (Amidate): Etomidate is an imidazole-derived IV hypnotic whose mechanism involves positive allosteric modulation of GABA-A receptors, with preferential activity at receptors containing β2 and β3 subunits.13 Its defining clinical characteristic is exceptional hemodynamic stability — it produces minimal changes in heart rate, blood pressure, and cardiac output compared to all other induction agents, making it the preferred induction agent for hemodynamically unstable patients who do not have the contraindication profile for ketamine.
Adverse effects: Etomidate produces myoclonus on induction in approximately 40–80% of patients, reduced by pre-treatment with midazolam or a small opioid induction dose. It is the most highly emetogenic of the IV induction agents. Its most clinically significant adverse effect is adrenocortical suppression: etomidate inhibits 11β-hydroxylase (the enzyme converting 11-deoxycortisol to cortisol in the adrenal cortex) by binding to its heme iron center, producing transient adrenal insufficiency lasting 12–24 hours after a single induction dose and substantially longer with continuous infusion.13 Continuous etomidate infusion for ICU sedation has been abandoned due to consistent and severe adrenocortical suppression.
Adrenal suppression controversy: The clinical significance of single-dose etomidate-induced adrenal suppression in septic shock has been debated for over four decades. Retrospective observational studies and some prospective trials suggested an association with increased 28-day mortality, longer ICU stay, and greater vasopressor requirements in septic shock patients intubated with etomidate. However, the KETASED randomized controlled trial comparing ketamine versus etomidate for RSI in ICU patients, and subsequent meta-analyzes, have not demonstrated statistically significant mortality harm from single-dose etomidate in sepsis, though the evidence does not fully exonerate it.13 Current practice varies by institution: many emergency medicine and critical care programs now favor ketamine for RSI in septic shock given its hemodynamic support and absence of adrenal concerns; some use routine corticosteroid supplementation (hydrocortisone 200 mg/day) in critically ill patients receiving etomidate; and others continue to use etomidate selectively based on hemodynamic profile. This debate exemplifies the difficulty in translating a well-established pharmacological mechanism into definitive outcome-level evidence in heterogeneous critically ill populations.
Remimazolam is an ultra-short-acting benzodiazepine approved by the FDA in 2020 for procedural sedation in adults — the first new benzodiazepine to reach the US market in decades. Its defining pharmacological feature is a unique ester linkage in its molecular structure that is cleaved by non-specific tissue esterases to an inactive carboxylic acid metabolite, producing a context-insensitive ultra-short duration of action with recovery times of approximately 5–10 minutes after cessation of infusion, independent of infusion duration — in sharp contrast to midazolam, whose recovery time increases substantially with prolonged infusion due to peripheral compartment accumulation.16 This pharmacokinetic profile makes remimazolam highly titratable, with predictable offset that does not require reversal in most cases. Standard dosing for procedural sedation is an initial IV dose of 5 mg over 1 minute, with 2.5 mg supplemental doses every 2 minutes as needed. Remimazolam acts at the benzodiazepine binding site on GABA-A receptors and is fully reversible with flumazenil — a meaningful distinction from propofol, for which no reversal agent exists. It has minimal cardiovascular effects compared to propofol, making it potentially advantageous in hemodynamically fragile patients. Remimazolam is metabolized independently of cytochrome P450 (CYP450) enzymes, resulting in no clinically significant pharmacokinetic drug interactions through this pathway — an advantage over midazolam in patients on CYP3A4 (cytochrome P450 3A4) inhibitors or inducers. It is a Schedule IV controlled substance
DEFINING THE SEDATION SPECTRUM: The American Society of Anesthesiologists (ASA) defines four levels of sedation along a continuum that is clinically important for understanding the risks and monitoring requirements of sedative administration:14
Minimal sedation (anxiolysis): Patients respond normally to verbal commands. Cognitive function and coordination may be mildly impaired, but ventilatory and cardiovascular function are unaffected. Airway protective reflexes remain intact. Example: oral premedication with a low-dose benzodiazepine.
Moderate sedation/analgesia (previously "conscious sedation"): Patients respond purposefully to verbal commands, either alone or accompanied by light tactile stimulation. No airway intervention is required; spontaneous ventilation is adequate and cardiovascular function is maintained. Example: IV midazolam and fentanyl for colonoscopy.
Deep sedation/analgesia: Patients cannot be easily aroused but respond purposefully following repeated or painful stimulation. Spontaneous ventilation may be inadequate, and patients may require assistance maintaining their airway. Cardiovascular function is usually maintained. Example: propofol sedation for complex endoscopic procedure.
General anesthesia: Patients are not arousable, even with painful stimulation. Ventilatory function is often impaired and frequently requires assistance. Cardiovascular function may also be impaired.
The clinical significance of this continuum is that patients can move between levels unintentionally, and providers must be trained to recognize and manage at least one level deeper than the target level. This underlies the ASA requirement that procedural sedation beyond minimal anxiolysis be administered and monitored by personnel with the training and equipment to manage at least deep sedation and airway emergencies.
MONITORING PRINCIPLES: Appropriate monitoring of sedated patients includes continuous pulse oximetry, continuous cardiac monitoring, non-invasive blood pressure monitoring at appropriate intervals, capnography (end-tidal CO2 monitoring) for moderate and deep sedation — increasingly recognized as superior to pulse oximetry for detecting early hypoventilation (SpO2 desaturation lags behind ventilatory depression by several minutes, particularly in patients receiving supplemental oxygen) — and assessment of sedation depth using validated scales. The Richmond Agitation-Sedation Scale (RASS) and the Sedation-Agitation Scale (SAS) are the most widely validated tools for sedation assessment in ICU patients.15 Target sedation depth should be individualized and the lightest level consistent with patient comfort and procedural requirements should be maintained — deep sedation and general anesthesia are associated with worse outcomes when applied indiscriminately in critically ill patients.
ICU SEDATION PRINCIPLES — ICU liberation bundle (ABCDEF) BUNDLE: Contemporary ICU sedation practice has moved decisively away from deep continuous sedation toward targeted light sedation with daily spontaneous awakening trials (SATs) as part of the ABCDEF bundle (Assess, Prevent, and Manage Pain; Both spontaneous awakening trial (SAT) and spontaneous breathing trial (SBT); Choice of analgesia and sedation; Delirium assess, prevent, and manage; Early mobility and exercise; Family engagement).15 Multiple randomized trials have demonstrated that protocolized light sedation — targeting RASS 0 to -2 rather than -3 to -5 — is associated with shorter duration of mechanical ventilation, reduced ICU length of stay, and better cognitive outcomes compared to deeper sedation strategies. The principle of analgesia-first sedation (ensuring adequate pain control before adding sedatives) reflects the understanding that inadequate analgesia is frequently the driver of patient agitation and distress in the ICU.
The clinical evidence base for dexmedetomidine in ICU sedation has been substantially shaped by two landmark randomized controlled trials. The Maximizing Efficacy of Targeted Sedation and Reducing Neurological Dysfunction trial (MENDS) trial (Maximizing Efficacy of Targeted Sedation and Reducing Neurological Dysfunction) randomized 106 mechanically ventilated adults to dexmedetomidine versus lorazepam infusion and found that dexmedetomidine-treated patients spent more time at the target RASS sedation score, had more days alive without delirium or coma, and had less cognitive impairment at hospital discharge.17 This trial provided foundational evidence for the superiority of dexmedetomidine over benzodiazepine infusions for ICU sedation and contributed directly to guideline recommendations against routine midazolam or lorazepam infusions for most ICU patients. The MENDS2 (Maximizing Efficacy of Targeted Sedation and Reducing Neurological Dysfunction 2) trial extended this evidence by comparing dexmedetomidine to propofol in 437 mechanically ventilated adults with septic shock or respiratory failure and brain dysfunction. MENDS2 found no significant overall difference in days alive without delirium or coma between the two agents, but identified a pre-specified subgroup benefit for dexmedetomidine in patients with hypoactive delirium — suggesting that the choice between propofol and dexmedetomidine may be guided by delirium phenotype and hemodynamic status rather than a universal preference.17 Collectively, these trials establish that dexmedetomidine is superior to benzodiazepine infusions for most ICU sedation needs, approximately equivalent to propofol for delirium outcomes in most patients, and uniquely advantageous in maintaining arousability — a property that supports neurological assessment, patient cooperation, and early mobilization that no other IV sedative can replicate.
CYP450 INDUCTION BY BARBITURATES: Phenobarbital is one of the most potent clinical cytochrome P450 (CYP450) inducers known, with meaningful induction of CYP1A2 (cytochrome P450 1A2), CYP2B6 (cytochrome P450 2B6), CYP2C9 (cytochrome P450 2C9), CYP2C19 (cytochrome P450 2C19), CYP3A4 (cytochrome P450 3A4), and UDP-glucuronosyltransferases (UGTs), as well as P-glycoprotein (P-gp).1 The clinical implications are broad and clinically dangerous if not recognized:
Warfarin: CYP2C9 induction increases warfarin metabolism, dramatically reducing anticoagulant effect. International normalized ratio (INR) monitoring and dose adjustment are essential when phenobarbital is started or stopped.
Oral contraceptives: CYP3A4 induction accelerates metabolism of ethinyl estradiol and progestins, reducing contraceptive efficacy. Alternative or additional contraceptive methods are required.
Antiretroviral therapy: Many protease inhibitors and non-nucleoside reverse transcriptase inhibitors (NNRTIs) are CYP3A4 substrates; phenobarbital can reduce their levels to subtherapeutic concentrations, with risk of virological failure.
Tricyclic antidepressants: CYP2D6 (cytochrome P450 2D6) and CYP2C19 induction reduces TCA plasma levels.
Antifungals (azoles): Reduced azole levels due to CYP3A4 induction.
Newer antiepileptic drugs: Lamotrigine, tiagabine, zonisamide, and felbamate levels are all reduced by phenobarbital coadministration.
CYP induction develops over days to weeks of phenobarbital administration (enzyme induction requires de novo protein synthesis) and similarly takes weeks to resolve after discontinuation. This means drug interactions are not immediate upon starting phenobarbital but can appear insidiously, and dosing adjustments for affected co-medications must be re-evaluated when phenobarbital is stopped.
OVERDOSE PRINCIPLES FOR BARBITURATES AND OTHER SEDATIVES: Overdose management for barbiturates, propofol (typically in the context of propofol infusion syndrome (PRIS) rather than intentional overdose), and other sedatives is discussed in detail in CNS-04. Key principles relevant here:
Barbiturate overdose is characterized by progressive CNS and respiratory depression, cardiovascular depression (hypotension, reduced cardiac output), hypothermia, and coma. Unlike benzodiazepine overdose, there is no specific reversal agent for barbiturate toxicity — management is purely supportive, with mechanical ventilation for respiratory failure, vasopressors for hypotension, temperature management, and multi-dose activated charcoal for phenobarbital (due to enterohepatic recirculation, urinary alkalinization with sodium bicarbonate to enhance renal elimination is used specifically for phenobarbital overdose).1
Brodie MJ, Kwan P. Current position of phenobarbital in epilepsy and its future. Epilepsia. 2012;53(Suppl 8):40–46.
doi:10.1111/epi.12027Olsen RW, Li GD. GABA-A receptors as molecular targets of general anesthetics: identification of binding sites provides clues to allosteric modulation. Can J Anaesth. 2011;58(2):206–215.
doi:10.1007/s12630-010-9429-7Trinka E, Kalviainen R. 25 years of advances in the definition, classification and treatment of status epilepticus. Seizure. 2017;44:65–73.
doi:10.1016/j.seizure.2016.11.001Painter MJ, Scher MS, Stein AD, et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. N Engl J Med. 1999;341(7):485–489.
doi:10.1056/NEJM199908123410704Tidwell WP, Thomas TL, Pouliot JD, Canonico AE, Webber AJ. Treatment of alcohol withdrawal syndrome: phenobarbital vs CIWA-Ar protocol. Am J Crit Care. 2018;27(6):454–460.
doi:10.4037/ajcc2018745Roberts I. Barbiturates for acute traumatic brain injury. Cochrane Database Syst Rev. 2000;(2):CD000033.
doi:10.1002/14651858.CD000033Seger DL. Chloral hydrate — a dangerous sedative for overdose patients? Pediatr Emerg Care. 1994;10(6):349–350.
Gammans RE, Stringfellow JC, Hvizdos AJ, et al. Use of buspirone in patients with generalized anxiety disorder and coexisting depressive symptoms: a meta-analysis of eight randomized, controlled studies. Neuropsychobiology. 1992;25(4):193–201.
doi:10.1159/000118837Miller RD, ed. Miller's Anesthesia. 8th ed. Philadelphia, PA: Elsevier Saunders; 2015. Chapters 17–18 (Intravenous Anesthetics).
Krajcova A, Waldauf P, Andel M, Duska F. Propofol infusion syndrome: a structured review of experimental studies and 153 published case reports. Crit Care. 2015;19(1):398.
doi:10.1186/s13054-015-1112-5Wunsch H, Kahn JM, Kramer AA, Rubenfeld GD. Dexmedetomidine in the care of critically ill patients from 2001 to 2007: an observational cohort study. Anesthesiology. 2010;113(2):386–394.
doi:10.1097/ALN.0b013e3181e74116Green SM, Roback MG, Kennedy RM, Krauss B. Clinical practice guideline for emergency department ketamine dissociative sedation: 2011 update. Ann Emerg Med. 2011;57(5):449–461.
doi:10.1016/j.annemergmed.2010.11.030Bruder EA, Ball IM, Ridi S, Pickett W, Hohl C. Single induction dose of etomidate versus other induction agents for endotracheal intubation in critically ill patients. Cochrane Database Syst Rev. 2015;(1):CD010225.
doi:10.1002/14651858.CD010225.pub2American Society of Anesthesiologists. Continuum of depth of sedation: definition of general anesthesia and levels of sedation/analgesia. ASA Standards, Guidelines and Statements. Approved 2019.
Devlin JW, Skrobik Y, Gélinas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med. 2018;46(9):e825–e873.
doi:10.1097/CCM.0000000000003299Kilpatrick GJ. Remimazolam: non-clinical and clinical profile of a new sedative/anesthetic agent. Front Pharmacol. 2021;12:690875.
doi:10.3389/fphar.2021.690875Pandharipande PP, Pun BT, Herr DL, et al. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. JAMA. 2007;298(22):2644–2653.
doi:10.1001/jama.298.22.2644